Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Fulminant Secondary HLH Following EBV Reactivation in an Adult With Trisomy 21 After Teplizumab Treatment for Stage 2 Type 1 Diabetes. Local targets link to admitted publications; unresolved targets remain external evidence.
An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes
10.1056/nejmoa1902226 · 2019 · External reference
Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association
10.2337/dc15-1419 · 2015 · External reference
Classification and diagnosis of diabetes: Standards of Care in Diabetes—2025
10.2337/dc25-s002 · 2025 · External reference
Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years
10.1128/jcm.42.8.3381-3387.2004 · 2004 · External reference
Serological diagnosis of Epstein-Barr virus infection: problems and solutions
10.5501/wjv.v1.i1.31 · 2012 · External reference
Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome
10.1002/art.38690 · 2014 · External reference
Treatment of Epstein-Barr virus-induced hemophagocytic lymphohistiocytosis with rituximab-containing chemoimmunotherapeutic regimens
10.1111/bjh.12386 · 2013 · External reference
Toward disease-modifying therapies in type 1 diabetes: focus on teplizumab
10.2337/dci25-0066 · 2026 · External reference
Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves β-cell function
10.2337/dc23-0675 · 2023 · External reference
Trisomy 21 consistently activates the interferon response
10.7554/elife.16220 · 2016 · External reference
Three copies of four interferon receptor genes underlie a mild type I interferonopathy in Down syndrome
10.1007/s10875-020-00803-9 · 2020 · External reference
Immune dysregulation in children with Down syndrome
10.3389/fped.2020.00073 · 2020 · External reference
Epstein-Barr virus and hemophagocytic lymphohistiocytosis
10.3389/fimmu.2017.01902 · 2017 · External reference
Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes
10.1172/jci177492 · 2024 · External reference
Teplizumab treatment for stage 2 type 1 diabetes: a real-world evaluation of metabolic and immunological outcomes
10.1007/s00125-025-06646-6 · 2026 · External reference
Latent EBV enhances the efficacy of anti-CD3 mAb in type 1 diabetes
10.1038/s41467-025-60276-5 · 2025 · External reference
Unresolved reference
External reference
